Home  |  Publications  |  Conferences   |  Join  |  Contact
                           
 
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals

Open Access
 
 
home » antivirals-antiretrovirals
 
 

Upcoming Special Issues

Special issue entitled: "Antiviral Drugs: Discovery & Development" has been edited by
Editor Image

Qianjun LI
Division of Infectious Diseases
Department of Medicine
University of Alabama at Birmingham
USA
Tel. 205-975-7601
Fax 205-934-5600
E-mail: liq@uab.edu

University Logo
Special issue entitled: "Global epidemiology of HIV/AIDS, STDs & STIs" has been edited by
Editor Image

Ludgleydson Araujo
Professor
Department of Psychology
Federal University of Piaui
Brazil
E-mail: ludgleydson@yahoo.com.br

Read More»
 

About the Journal

Welcome Message
Welcome to the Journal of Antivirals and Antiretrovirals (JAA): An open-access, multidisciplinary journal for the discovery and development of antiviral drugs.
I welcome you to a truly interdisciplinary journal which attracts the interest of scientists from various fields such as systems biology, chemistry, virology, and the clinical sciences.
Impact Factor: 1.27*
Index Copernicus Value: 4.86
H-Factor: 4
The Journal of Antivirals & Antiretrovirals (JAA) paves the way to discovery and development of antiviral drugs, compounds, and clinical methods to prevent viral infections. Importantly, JAA provides the opportunity to inform researchers, clinicians, and others working in the field of antiviral drugs and therapies. JAA is an internationally recognized journal for scientists involved in basic, applied, and clinical aspects of antiviral and antiretroviral research. It is known that many viruses emerge and re-emerge threatening both animal and human populations. Zoonotic viruses can cause extensive morbidity and mortality; however, preventive vaccines that provide protection are available for only a limited number of viruses.
The primary current therapeutic approach against viral diseases is to target viral components that are essential for replication. There are a number of disadvantages targeting viral components including the limited number of druggable viral targets because viruses have a small genome, as well as the rapid development of drug resistance. New drug therapies combine antivirals to increase efficacy and to avoid the development of drug resistant strains. These strategies are effective for viruses such as HIV, but clearly there is a need to expand our drug arsenal to address the wide diversity of viruses. This pathway relies on alternative strategies for drug discovery, such as examining the virus-host interface. 
High-throughput RNA interference (RNAi) technology is a platform-enabling technology that allows for rapid searching and validation of biologically relevant target genes in the host. RNAi can be used to silence each and every gene in a host to ask what genes are needed for virus replication. Perhaps the greatest challenge is identify and validate the host genes and pathways they intersect among all the interactions relevant to virus replication. Here, antiviral drugs targeting host genes/factors can be discovered that markedly expand the number of druggable targets that can be temporarily silenced to prevent virus replication. This genome-wide exploration of virus-host interactions allows for a paradigm change in drug discovery because it provides critical host gene/pathway information allowing for drug rescue and repurposing. This systems-based approach to antiviral drug discovery integrates multiple ‘-omics’ approaches because much is learned about host genes co-opted by the virus for metabolomics, and proteins usurped for viral protein trafficking and viral packaging (proteomics), and the like. This information helps to find drugs lacking undesired side effects, and uses a rational approach in drug screening.
As the Editor-in-Chief of Journal of Antivirals & Antiretrovirals, I believe the strength of this open access journal is determined by the quality of manuscripts that it receives, and by the assembly of its editorial board that must encourage contributions from leading investigators. As JAA is an open-access, multidisciplinary journal for the discovery and development of antiviral drugs, it allows for rigorous review and rapid publication without unnecessary delay or expense. I expect JAA to become a venue for top-quality manuscripts and look forward to reading your contributions. Best.
*Unofficial 2014 Impact Factor was established by dividing the number of articles published in 2012 and 2013 with the number of times they are cited in 2014 based on Google search and the Scholar Citation Index database. If ‘X’ is the total number of articles published in 2012 and 2013, and ‘Y’ is the number of times these articles were cited in indexed journals during 2014 than, impact factor = Y/X
 
Aims and Scope
 

Recently published articles

 
Immune Activation in HIV Infection: Friend or Foe

Preeti Bharaj and Harendra Singh Chahar

 
 
Isolation and Molecular Diagnosis of Orf Virus from Small Ruminants and Human in Egypt

Gamil SG Zeedan, Abeer M Abdalhamed, Nahed H Ghoneim and Alaa A Ghazy

 
Awareness, Knowledge and Misconceptions about Ebola Virus Disease (EVD) in a Family Practice Setting in Nigeria, West Africa

Rasaki O Shittu, Musa A Sanni, Louis O Odeigah, Akanbi II AA, Abdullateef G Sule, Salamat Isiaka-Lawal and Aderibigbe SA

 
 
 
 
 
 
© 2008-2015 OMICS Group - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version